glp 1 and bowel movements The role of GLP-1 RA in inflammatory disease. The GLP-1 RA Clinical Recommendations to Manage Gastrointestinal

Clinical trials demonstrate significant weight reduction, with patients losing approximately 15% of body weight over 68 weeks with semaglutide (STEP 1 trial) and up to 21% with tirzepatide 15 mg over 72 weeks (SURMOUNT-1 trial)

This rebound occurs because appetite-regulating hormones return to baseline, and established eating habits may resurface

All of this together can also signal your brain that youre full

Three to four is ideal if your recovery allows it

Our bodies have experienced an insidious decline over the past half-century that has been caused by never-ending consumption of foods that can trigger our brains addictive circuits